Search Results

The size of the disease relevant IgE antibody fraction in relation to `total-IgE' predicts the efficacy of anti-IgE (Xolair^®) treatment

Authors: Johansson, S. G. O.; Nopp, A.; Öman, H.; Ankerst, J.; Cardell, L. O.; Grönneberg, R.; Matsols, H.; Rudblad, S.; Strand, V.; Stålenheim, G.

Source: Allergy, Volume 64, Number 10, October 2009 , pp. 1472-1477(6)

Publisher: Blackwell Publishing

Baseline characteristics of patients enrolled in EXCELS: a cohort study

Authors: Long, Aidan A.; Fish, James E.; Rahmaoui, Abdelkader; Miller, Mary K.; Bradley, Mary S.; Taki, Hassan N.; Demeo, Anthony N.; Tilles, Stephen A.; Szefler, Stanley J.

Source: Annals of Allergy, Asthma and Immunology, Volume 103, Number 3, September 2009 , pp. 212-219(8)

Publisher: American College of Allergy, Asthma, & Immunology

A case of severe refractory chronic urticaria: A novel method for evaluation and treatment

Authors: Otto, Hans F.; Calabria, Christopher W.

Source: Allergy and Asthma Proceedings, Volume 30, Number 3, May-June 2009 , pp. 333-337(5)

Publisher: OceanSide Publications, Inc

Safety and tolerability of omalizumab

Authors: Corren, J.; Casale, T. B.; Lanier, B.; Buhl, R.; Holgate, S.; Jimenez, P.

Source: Clinical & Experimental Allergy, Volume 39, Number 6, June 2009 , pp. 788-797(10)

Publisher: Blackwell Publishing

Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma

Authors: Kopp, M. V.; Hamelmann, E.; Zielen, S.; Kamin, W.; Bergmann, K.-C.; Sieder, C.; Stenglein, S.; Seyfried, S.; Wahn, U.

Source: Clinical & Experimental Allergy, Volume 39, Number 2, February 2009 , pp. 271-279(9)

Publisher: Blackwell Publishing

Geohelminth infections: a review of the role of IgE and assessment of potential risks of anti-IgE treatment

Authors: Cooper, P. J.; Ayre, G.; Martin, C.; Rizzo, J. A.; Ponte, E. V.; Cruz, A. A.

Source: Allergy, Volume 63, Number 4, April 2008 , pp. 409-417(9)

Publisher: Blackwell Publishing

The role of anti-IgE immunoglobulin therapy in nasal polyposis: A pilot study

Authors: Penn, Renee; Mikula, Suzette

Source: American Journal of Rhinology, Volume 21, Number 4, July-August 2007 , pp. 428-432(5)

Publisher: OceanSide Publications, Inc

Omalizumab (Xolair) in patients with steroid-resistant asthma: Lessons to be learnt

Authors: THOMPSON, PhilipJ.; MISSO, NeilL.; WOODS, John

Source: Respirology, Volume 12, Supplement 3, November 2007 , pp. S29-S34(1)

Publisher: Blackwell Publishing

CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment

Authors: Nopp, A.; Johansson, S. G. O.; Ankerst, J.; Palmqvist, M.; Öman, H.

Source: Allergy, Volume 62, Number 10, October 2007 , pp. 1175-1181(7)

Publisher: Blackwell Publishing

Omalizumab (Xolair) in children with seasonal allergic rhinitis: Leukotriene release as a potential in vitro parameter to monitor therapeutic effects

Authors: Kopp, Matthias Volkmar; Stenglein, Stefan; Kamin, Wolfgang; Friedrichs, Frank; von Berg, Andrea; Zielen, Stefan; Hamelmann, Eckard; Wahn, Ulrich; Kuehr, Joachim

Source: Pediatric Allergy and Immunology, Volume 18, Number 6, September 2007 , pp. 523-527(5)

Publisher: Blackwell Publishing

FDA boxed warning of anaphylaxis risk with Xolair

Source: Reactions, Volume 1, Number 1159, 2007-07-07 , pp. 2-2(1)

Publisher: Adis International

FDA in favour of boxed warning for Xolair

Source: Reactions, Volume 1, Number 1141, 2007-03-03 , pp. 4-4(1)

Publisher: Adis International

FDA in favour of boxed warning for Xolair

Source: Inpharma, Volume 1, Number 1577, 2007-03-03 , pp. 20-20(1)

Publisher: Adis International

IgE, Allergic Diseases, and Omalizumab

Author: DuBuske, L. M.

Source: Current Pharmaceutical Design, Volume 12, Number 30, October 2006 , pp. 3929-3944(16)

Publisher: Bentham Science Publishers

Omalizumab: a future innovation for treatment of severe ocular allergy?

Authors: Williams, Patricia B; Sheppard Jr, John D

Source: Expert Opinion on Biological Therapy, Volume 5, Number 12, 1 December 2005 , pp. 1603-1609(7)

Publisher: Informa Healthcare

Safety and tolerability of omalizumab (Xolair®), a recombinant humanized monoclonal anti-IgE antibody

Authors: Deniz, Yamo; Gupta, Niroo

Source: Clinical Reviews in Allergy and Immunology, Volume 29, Number 1, February 2005 , pp. 31-48(18)

Publisher: Humana Press

Omalizumab [Xolair; Novartis] has been launched in Canada for the treatment of moderate-to-severe, persistent asthma

Source: Inpharma, Volume 1, Number 1491, 2005-06-11 , pp. 22-22(1)

Publisher: Adis International

On the Prediction of the Human Response: A Recycled Mechanistic Pharmacokinetic/Pharmacodynamic Approach

Authors: Meno-Tetang Guy M. L.; Lowe Philip J.

Source: Basic & Clinical Pharmacology & Toxicology, Volume 96, Number 3, March 2005 , pp. 182-192(11)

Publisher: Blackwell Publishing

Omalizumab in the treatment of allergy and asthma

Authors: Lanier, Bob; Carr, Warner

Source: Therapy, Volume 1, Number 1, September 2004 , pp. 25-30(6)

Publisher: Future Medicine

Unanswered questions on omalizumab (Xolair) patient selection and follow-up

Authors: Lanier, Bobby; Marshall, Gailen D.

Source: Annals of Allergy, Asthma and Immunology, Volume 92, Number 2, February 2004 , pp. 198-200(3)

Publisher: American College of Allergy, Asthma, & Immunology